Treatment of Warm Autoimmune Hemolytic Anemia (WAIHA)

Background

• ~50-60% of cases are secondary (lymphoma, SLE, CLL, drugs, etc.) - always search for an underlying cause
• Only one-third of patients achieve complete remission off-treatment at 1 year
• Even "primary" WAIHA can precede non-Hodgkin lymphoma by years - long-term follow-up is mandatory

When to Treat

• Mild compensated hemolysis with near-normal hemoglobin: observation is acceptable
• All others with significant anemia or symptomatic hemolysis require treatment

FIRST-LINE: Corticosteroids

• ~50-60% of responders are corticosteroid-dependent - relapse when dose drops below ~10-15 mg/day
• Long-term prednisone at >10-15 mg/day carries significant adverse effects
• IVIG (2 g/kg over 2 days) has only limited efficacy and should be reserved as rescue therapy for severe, transfusion-dependent WAIHA refractory to steroids

SECOND-LINE Treatment

1. Rituximab (preferred second-line)

• Risk of late-onset neutropenia and opportunistic infections (e.g., Pneumocystis jirovecii pneumonia)
• PCP prophylaxis: Trimethoprim-sulfamethoxazole 160/800 mg three times per week
• Before rituximab (when splenectomy may be needed later): vaccinate against S. pneumoniae, H. influenzae type B, and N. meningitidis at least 2 weeks prior

2. Splenectomy

• Historically the standard second-line option; now reserved for those who have failed both corticosteroids AND rituximab
• Sustained response rate: 60-70%
• Laparoscopic splenectomy has perioperative mortality <1%
• Avoid in children <5-7 years if possible

• Overwhelming post-splenectomy sepsis (unpredictable)
• Postoperative thromboembolic events (especially splanchnic veins)

• Perioperative LMWH is recommended, especially if antiphospholipid antibodies are positive
• Pre-splenectomy vaccination is mandatory

THIRD-LINE and Beyond

Danazol (corticosteroid-sparing)

• Attenuated androgen analogue at 400-800 mg/day
• Useful as a steroid-sparing agent when daily prednisone >15 mg is required
• Limitations: androgenic side effects (limits use in women), potential hepatotoxicity restricts long-term use in men

Immunosuppressive / Cytotoxic Agents

For Multi-refractory WAIHA

• Bortezomib + dexamethasone - promising results reported under expert supervision

Transfusion

• Transfusion should be given when clinically necessary (severe symptomatic anemia)
• Cross-matching is difficult due to the autoantibody, but should not be withheld in life-threatening situations
• Use the least incompatible blood

Treatment Algorithm Summary

Diagnosis of primary WAIHA
        ↓
FIRST-LINE: Prednisone 1-2 mg/kg/day x 3-4 weeks
        ↓
Response? 
  YES → Taper slowly; maintain ≥3 months after CR
  NO / Corticosteroid-dependent (>10-15 mg/day needed)?
        ↓
SECOND-LINE: Rituximab 375 mg/m² x 4 weeks
        ↓
Response?
  YES → Monitor; long-term follow-up
  NO?
        ↓
SECOND-LINE: Splenectomy (laparoscopic)
        ↓
Refractory to all above?
        ↓
THIRD-LINE: Danazol, Azathioprine, Cyclophosphamide, 
            Mycophenolate, Cyclosporine
            OR Bortezomib + Dexamethasone (multirefractory)

Harrison's 22E (2025) - WAIHA Treatment

First-Line

"Rituximab (anti-CD20), previously regarded as second-line treatment, is increasingly being used at a relatively low dose (100 mg/week × 4), together with prednisone as part of first-line treatment. It is especially encouraging that this approach seems to reduce the rate of relapse, a common occurrence in AIHA."

• Prednisone 1 mg/kg/day - standard first-line
• Rituximab 100 mg/week × 4 - now used upfront alongside prednisone as first-line combination (NOT just second-line)
• This combination is favored because it reduces relapse rates

For Relapse / Refractory Cases

Comparing Harrison vs Goldman-Cecil on Rituximab

Latest WAIHA Clinical Guidelines & Protocols (2024-2025)

Regulatory Status (as of July 2026)

Important: As of 2025-2026, there are no FDA-approved therapies specifically licensed for WAIHA - all existing treatments (steroids, rituximab, etc.) are used off-label. Nipocalimab (Imaavy) received FDA Priority Review in Q2 2026 for WAIHA; Phase 2/3 ENERGY trial showed a statistically significant durable hemoglobin response (~3x more patients met primary endpoint vs. placebo at week 24). FDA approval is expected but not yet granted for WAIHA specifically.

Diagnosis (Guideline Consensus)

• Hemolysis markers required: elevated unconjugated bilirubin, elevated LDH, elevated reticulocyte count, reduced haptoglobin, spherocytes on smear
• DAT is the primary diagnostic tool: start with polyspecific antiserum; if positive, monospecific DAT for IgG/IgA/IgM/C3d for subclassification
• WAIHA confirmed when DAT is IgG-only or IgG + C3d positive, with clinically significant cold-reactive antibody excluded
• Search for secondary causes in all patients (lymphoma, SLE, CLL, drugs, checkpoint inhibitors)

Treatment Algorithm (2024-2025 Consensus)

FIRST-LINE: Corticosteroids

SECOND-LINE: After Steroid Failure or Corticosteroid-Dependence

• Overall response rate: ~75% at 1 year
• Mandatory PCP prophylaxis: TMP-SMX 160/800 mg three times/week (especially in patients also on corticosteroids - 2026 French nationwide study confirmed 17.6% hospitalization rate from infection in first 6 months)
• Pre-rituximab vaccination (if splenectomy may be needed): vaccinate against S. pneumoniae, H. influenzae type B, N. meningitidis at least 2 weeks before
• Also consider: Cyclosporine 2-5 mg/kg/day or Azathioprine 1-2 mg/kg/day (100% consensus in Asia-Pacific Delphi 2025)

THIRD-LINE: After Second-Line Failure

Note for LMIC settings: Recent viewpoints (2024) suggest that in countries where rituximab is unaffordable, splenectomy may be moved up to second-line as a cost-effective alternative.

Transfusion Guidance (Updated 2024-2025)

• ABO, Rh, and Kell matched units should be used
• The concept of "least incompatible blood" is now considered obsolete
• Transfusion must NOT be delayed in life-threatening situations due to serological complexity
• Cross-matching difficulties should not be a reason to withhold blood in emergencies

Supportive Care (Guideline Consensus)

Secondary WAIHA

• Treating the underlying disease is always the first choice (100% consensus) - remission of the underlying disease may resolve the hemolysis
• For WAIHA secondary to connective tissue disease (CTD): corticosteroids alone, or steroids + MMF, or treat CTD first (all ≥90% consensus)

Emerging Therapies Under Investigation (2025-2026)

Key Takeaway: How Guidelines Have Evolved (2020 → 2025)

• First International Consensus Meeting on AIHA (Jäger et al., 2020) - primary global guideline reference
• Asia-Pacific Delphi Expert Consensus 2025 - most recent consensus document
• Barcellini & Fattizzo, Blood Reviews 2026 - latest review of new frontiers
• BSH/BCSH guidelines (referenced via Rare Disease Advisor)
• Harrison's Principles of Internal Medicine 22E (2025)

Can You Escalate from Rituximab 100 mg to 375 mg/m² After Non-Response?

Short Answer: Yes, this is a reasonable clinical approach - but there is no formal RCT evidence specifically for this escalation strategy.

What the Evidence Actually Says

"Usually we tend to use the low dose (100 mg/week × 4) in patients with DAT positive for IgG only. Whilst in patients with DAT positive for IgG AND complement fraction (C3d), we tend to use the standard dose of 375 mg/m²."

What Happens When Low-Dose Rituximab Fails?

• CD20 may not have been adequately saturated
• In this case, a full standard-dose course (375 mg/m² × 4) is biologically reasonable and is what most experts would do
• Check CD19/CD20 count first - if B cells are still present/recovering, 375 mg/m² is a justified next step

• The problem is not B-cell depletion but residual plasma cells or non-B-cell mechanisms
• Escalating to 375 mg/m² will likely not help (same mechanism, already depleted)
• Here you should move to a different class: splenectomy, fostamatinib, daratumumab, or clinical trial

"The Committee reviewed evidence for the use of rituximab at 100 mg/m² weekly × 4 doses. However, due to the limited evidence of benefit in comparison to standard dosing, the lower dosing schedule is NOT recommended in South East London. For ALL types of AIHA, rituximab is recommended at 375 mg/m² weekly × 4 doses."

Practical Recommendation

Patient failed steroids + rituximab 100 mg × 4
            ↓
Check B-cell count (CD19/CD20)
            ↓
B cells NOT depleted          B cells depleted
(poor CD20 saturation)        (mechanism beyond B cells)
            ↓                           ↓
Standard-dose rituximab        Do NOT repeat rituximab
375 mg/m² × 4 weeks           Move to next line:
(reasonable escalation)        - Splenectomy
                               - Fostamatinib
                               - Daratumumab
                               - Clinical trial

Bottom Line

• Escalating to 375 mg/m² is clinically defensible if B cells are not depleted, but there is no RCT data for this specific escalation
• The two doses target the same mechanism (CD20/B-cell depletion) - so if B cells are already gone, escalation won't help
• Checking a peripheral B-cell count before re-dosing is the key decision point
• If B cells are depleted and the patient still failed, the guidelines are clear: move to splenectomy, fostamatinib (Syk inhibitor), or enrol in a clinical trial

Management After Steroid Response in WAIHA

Step 1 - Define the Response First

Step 2 - Steroid Taper Protocol

• ~50-60% of patients are corticosteroid-dependent - hemolysis returns when dose drops below a threshold (~10-15 mg/day)
• Premature stopping is the most common cause of early relapse
• Overall, only 1 in 3 patients achieves durable complete remission off-treatment at 1 year (Goldman-Cecil)

Step 3 - Monitor During Taper

• Hemoglobin - drop signals relapse
• Reticulocyte count - rising reticulocytes before Hb falls is an early relapse sign
• LDH, indirect bilirubin, haptoglobin - hemolysis markers
• DAT - may remain positive even in remission; do not use it alone to guide treatment decisions

Step 4 - What Happens After Taper? Three Scenarios

Patient responds to steroids
         ↓
    Taper slowly over 3-6 months
         ↓
    ┌────────────────────────────────────┐
    │                                    │
Sustained CR off           Relapse / Steroid-dependent
steroids (~33%)            (needs >10-15 mg/day to maintain PR)
    │                                    │
Monitor and                              ↓
follow up                    SECOND-LINE THERAPY
long-term*                   → Rituximab (preferred)
                             → If severe upfront: steroid + rituximab combination

Step 5 - Steroid-Sparing Strategies (If Dependent but Not Yet Failed)

Step 6 - Supportive Care Throughout

Summary Flow

Steroid response confirmed
        ↓
Maintain dose 3-4 weeks
        ↓
Slow taper → target stop within 3-6 months
        ↓
Sustained CR?          Corticosteroid-dependent?         Relapse?
    ↓                          ↓                             ↓
Long-term               Add steroid-sparing           Second-line:
follow-up               agent (danazol /              Rituximab
(watch for              azathioprine /                (± steroids)
lymphoma)               MMF)

Relapse Rates: Steroids Alone vs. Steroids + Low-Dose Rituximab in WAIHA

The Key RCT: Birgens et al. (2013) - Phase III Danish Randomized Trial

• 64 newly diagnosed WAIHA patients
• Randomized to: prednisolone alone (n=32) vs. prednisolone + rituximab 375 mg/m² × 4 (n=32)

"About 70% of patients treated with rituximab + prednisolone were still in remission at 36 months, compared with about 45% in the prednisolone-only group." - Birgens et al.

• Steroids alone: ~55%
• Steroids + rituximab: ~30%

Note: This Trial Used Standard-Dose Rituximab (375 mg/m²), NOT 100 mg

Low-Dose Rituximab (100 mg/week × 4) Data

Side-by-Side Summary

Important Caveat

Adding rituximab to steroids (at any dose) roughly halves the relapse rate at 3 years compared to steroids alone - from ~55% down to ~30-40%.